Table 2. Pretreatment and On-Treatment Predictors of Antiviral Effect, Non-Response and Relapse in Chronic Hepatitis C a.
| Factor | SVR | Non-Response | Relapse | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Patients With SVR (N = 124) | Patients Without SVR (N = 45) | P | Non-Response Patients (N = 22) | Response Patients (N = 147) | P | Patients With Relapse (N = 23) | Patients Without Relapse (N = 119) | P | |
| Age, y | 43 ± 13 | 44 ± 13 | 0.573 | 49 ± 11 | 42 ± 13 | 0.029 b | 43 ± 15 | 42 ± 13 | 0.736 |
| Sex (male: female) | 68 : 56 | 24 : 21 | 0.862 | 10 : 12 | 82 : 65 | 0.364 | 14 : 9 | 65 : 54 | 0.581 |
| ALT, IU/L | 76 ± 74 | 84 ± 72 | 0.460 | 71 ± 68 | 79 ± 74 | 0.615 | 80 ± 77 | 77 ± 75 | 0.333 |
| AST, IU/L | 66 ± 67 | 78 ± 67 | 0.226 | 67 ± 58 | 70 ± 68 | 0.870 | 75 ± 77 | 67 ± 67 | 0.435 |
| HCV-RNA, log10, IU/mL | 7.4 ± 1.6 | 8.8 ± 1.6 | 0.610 | 6.5 ± 0.7 | 6.1 ± 1.0 | 0.077 | 7.9 ± 1.5 | 7.5 ± 1.6 | 0.880 |
| HCV genotypes (1,6/2,3) | 90/34 | 43/2 | 0.001 b | 22/0 | 111/36 | 0.009 b | 20/3 | 88/31 | 0.181 |
| IL28B genotypes (CC/N-CC) | 112/12 | 28/17 | < 0.001 b | 13/9 | 127/20 | 0.002 b | 14/9 | 109/10 | < 0.001 b |
| RVR (RVR/N-RVR) | 89/35 | 10/35 | < 0.001 b | - | - | - | 8/15 | 87/32 | < 0.001 b |
| EVR (EVR/N-EVR) | 121/3 | 18/27 | < 0.001 b | - | - | - | 18/5 | 117/2 | < 0.001 b |
a Abbreviations: ALT, alanine aminotransferase; AST, aspartate transaminase; CC genotype of interleukin 28 single nucleotide polymorphism; EVR, early virologic response; IL28 CC; SVR, sustained viral response; RVR, rapid virologic response.
b Statistically significance was presented.